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Abstract
Background: To examine if the significantly associated SNPs derived from the genome wide allelic association study on the
AREDS cohort at the NEI (dbGAP) specifically confer risk for neovascular age-related macular degeneration (AMD). We
ascertained 134 unrelated patients with AMD who had one sibling with an AREDS classification 1 or less and was past the age
at which the affected sibling was diagnosed (268 subjects). Genotyping was performed by both direct sequencing and Sequenom
iPLEX system technology. Single SNP analyses were conducted with McNemar's Test (both 2 × 2 and 3 × 3 tests) and likelihood
ratio tests (LRT). Conditional logistic regression was used to determine significant gene-gene interactions. LRT was used to
determine the best fit for each genotypic model tested (additive, dominant or recessive).
Results: Before release of individual data, p-value information was obtained directly from the AREDS dbGAP website. Of the
35 variants with P < 10-6 examined, 23 significantly modified risk of neovascular AMD. Many variants located in tandem on 1q32-
q22 including those in CFH, CFHR4, CFHR2, CFHR5, F13B, ASPM and ZBTB were significantly associated with AMD risk. Of these
variants, single SNP analysis revealed that CFH rs572515 was the most significantly associated with AMD risk (P < 10-6).
Haplotype analysis supported our findings of single SNP association, demonstrating that the most significant haplotype,
GATAGTTCTC, spanning CFH, CFHR4, and CFHR2 was associated with the greatest risk of developing neovascular AMD (P <
10-6). Other than variants on 1q32-q22, only two SNPs, rs9288410 (MAP2) on 2q34-q35 and rs2014307 (PLEKHA1/HTRA1) on
10q26 were significantly associated with AMD status (P = .03 and P < 10-6 respectively). After controlling for smoking history,
gender and age, the most significant gene-gene interaction appears to be between rs10801575 (CFH) and rs2014307 (PLEKHA1/
HTRA1) (P < 10-11). The best genotypic fit for rs10801575 and rs2014307 was an additive model based on LRT. After applying
a Bonferonni correction, no other significant interactions were identified between any other SNPs.
Conclusion: This is the first replication study on the NEI dbGAP SNPs, demonstrating that alleles on 1q, 2q and 10q may
predispose an individual to AMD.
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Background
Advanced age-related macular degeneration (AMD) is the
most common cause of legal blindness in developed
countries. Clinically two forms of advanced AMD are rec-
ognized: geographic atrophy and neovascular. Geo-
graphic atrophy is characterized by a slow progressive
degeneration of the retinal pigment epithelium (RPE),
resulting in the gradual loss of the photoreceptors. The
neovascular form is characterized by the growth of new
abnormal blood vessels from beneath the retina that can
cause severe and rapid vision loss due to hemorrhage and
exudation. It is the neovascular form that is responsible
for the majority of debilitating vision loss due to AMD,
greatly impairing an individual's ability to read, drive and
recognize faces. The burden on public health is signifi-
cant, as in the U.S. alone, it is predicted that about 3 mil-
lion individuals over the age of 50 years will have
advanced AMD in at least one eye by 2020 [1].
Although the newest treatments for neovascular AMD
offer some chance of visual improvement, they require
invasive delivery methods, cannot prevent disease, and
have limited ability to reverse vision loss. Assessments of
an individual's risk of developing advanced AMD are
based on ocular findings in those who already have the
early stages. Methods are needed for determining which
members of the population are at highest risk of vision
loss due to AMD prior to the development of any signs of
the disease. The identification of genetic variants that
could be used as biomarkers would help to predict risk for
more advanced stages of AMD and possibly provide new
targets for therapeutic or behavioral intervention, thereby
reducing or preventing the incidence of this disease.
In an effort to correlate genotypes with advanced AMD
clinical phenotypes, the National Eye Institute (NEI) per-
formed a genome wide association study on the Age-
related eye disease study (AREDS) cohort consisting of
395 advanced AMD (both neovascular and geographic
atrophy) cases and 198 control subjects. Affymetrix and
Illumina 100 K arrays were used to test for individual SNP
(Single Nucleotide Polymorphism) associations [2,3]In
the study presented here, we sought to validate these find-
ings in samples from unrelated patients with only neovas-
cular AMD who had one sibling with normal maculae and
was past the age at which the affected sibling was diag-
nosed with neovascular AMD. We employed this
approach to examine if some or all of the NEI/NCBI
dbGAP SNPs specifically predisposed an individual to
AMD by studying subjects with and without the neovascu-
lar form of AMD. Our phenotypically well-defined cohort
of 268 subjects comprised 134 extremely discordant sib-
pairs; that is, pairs with one member in the upper 10% of
disease severity (affected sibling) and the other member
in the bottom 10–30% of disease severity (unaffected sib-
ling). Mathematical analyses indicate that the evaluation
of sibpairs who are extremely discordant for a quantita-
tive, multifactorial trait can be informative for identifying
the genetic variants that govern the trait [4]. Many studies
have suggested various ways for quantifying AMD but
they are not conclusive. However, we know from studies
based on prevalence of both early and late AMD that our
unaffected siblings likely represent the bottom 10%–30%
of the population and those with the most severe forms of
AMD (geographic atrophy or neovascular AMD) represent
the top 10% with respect to phenotype [5-10].
Moreover, extremely discordant sibpairs can provide a
robust alternative study design for finding an association
between a genetic variant and a complex disease to using
sibpairs with intermediate phenotypes [11] or case-con-
trols study design [12].
We have previously demonstrated that such types of sib-
pairs can be powerful in identifying the contribution that
many genetic variants, even those with a modest effect,
along with smoking make simultaneously to AMD suscep-
tibility [13,14]. We employed a combination of the
Sequenom iPLEX system technology and direct sequenc-
ing to genotype 35 variants in order to identify the contri-
bution that the dbGAP allelic risk factors make
independently, and in combination, along with smoking
to overall risk of developing neovascular AMD.
Results
We identified all 34 variants we sought to investigate in
our extremely discordant sibpair cohort of 268 Caucasian
subjects. In our analysis we also included CFH Y402H
which has been previously analyzed in this cohort [13].
No significant deviations from Hardy-Weinberg equilib-
rium for any of the variants studied were observed in the
unaffected siblings, indicating unlikely contamination of
our dataset. For genotype and allele frequencies for each
of these SNPs, please see Additional File 1.
The results of both types of McNemar's tests, likelihood
ratio tests and resulting P values for all 35 SNPs after con-
trolling for age, gender and smoking are shown in Table 1.
The resulting odds ratios, confidence intervals and mode
of inheritance resulting from the LRT also appear in Table
1. In addition to the Y402H CFH variant, 23 SNPs were
significantly associated with neovascular AMD risk (Table
1). PHASE produced similar results to SNPHAP for diplo-
type reconstruction so we focused the remainder of our
analysis using SNPHAP. Many variants located in tamdem
on 1q32-q22 including those in complement Factor H
(CFH), complement factor H-related 4 (CFHR4), comple-
ment factor H-related 2 (CFHR2), complement factor H-
related 5 (CFHR5), coagulation factor 13 subunit B
(F13B), abnormal spindle-like microcephaly associatedBMC Medical Genetics 2008, 9:51 http://www.biomedcentral.com/1471-2350/9/51
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(ASPM) and zinc finger and BTB domain containing 41
homolog (ZBTB41) were significantly associated with
AMD risk (Table 1). According to LRT, single SNP analysis
showed that CFH  rs572515 on 1q25 was the most
strongly associated SNP with AMD risk under an additive
model. All SNPs analyzed on 1q32-q22 except for F13B
rs2990510 were significantly associated with neovascular
AMD risk using the LRT (P < .01). SNP rs9288410 (MAP2)
on 2q35-q34 and SNP rs2014307 on 10q26 PLEKHA1/
HTRA1 were also associated with AMD risk (OR: 1.92;
95% C.I.: 0.89, 4.18; P = 0.03 and OR: 0.240; 95% C.I.:
0.11, .52; P < 10-4 respectively). According to ENSEMBL
[15], SNP rs2014307 is equidistant between the end of
PLEKHA1 and the beginning of HTRA1. Single SNP anal-
ysis in the 1q32-q22 region was confirmed by demon-
strating that the haplotype GATAGTTCTC for alleles
spanning CFH, CFHR4, and CFHR2 were associated with
the greatest risk of neovascular AMD (P < 10-6). These 9
SNPs, which included the Y402H CFH variant, spanned
the 1q31-1q32 region and formed two haplotype blocks
(Figure 1a and Figure 1b) that were in linkage disequilib-
rium (D' = 0.79) (Figure 1c) (see Table 2).
Table 3 shows the results for testing interaction, joint
effects and main effects of each significantly associated
SNP on chromosome 1 with rs2014307 on chromosome
10. After controlling for smoking, age and gender, the
resulting P values, odds ratios and 95% C.I. of each SNP,
while controlling for the other SNP, are shown. Almost all
of the combinations of SNP pairs tested showed no inter-
action at 0.05 level of significance, except for rs800292/
rs2014307 and rs3790414/rs2014307. However, neither
of these SNP pair combinations was significant after
applying a Bonferroni correction. Therefore, no interac-
tion is found in the joint effect and main effect analyses.
The most significant joint effect is observed between
rs10801575 and rs2014307 (P < 10-11). The LRT demon-
strated that CFH SNP rs10801575 fits best under a domi-
nant model whereas rs2014307 fits best under an additive
model. The main effect for each of these SNPs individually
is highly significant (OR: 3.16; 95% C.I.: 3.16, 7.347; P <
10-4and OR: 0.26; 95% C.I.: 0.13, .55; P < 10-6, respec-
tively).
Discussion
Inconsistency in replication of findings among studies
could possibly be due to population stratification, disease
heterogeneity, and/or diagnostic heterogeneity in pheno-
type among cases [12]. In the study presented here, using
phenotypically well defined extremely discordant sib-
pairs, we were able to confirm the NEI/NCBI dbGAP find-
ings for chromosomes 1, 2 and 10 in a Caucasian
population (mostly derived from the U.S.) employing a
different methodological design [2,3]. Moreover, our
findings suggest that specific genetic variants may predis-
pose to the neovascular form of AMD, as the dbGAP data
included cases with both neovascularization and geo-
graphic atrophy. On the other hand, it could be that our
use of the Bonferroni correction was overly stringent
(given the LD between many of the SNPs) and this could
account for the fact that we only observed a portion of the
variants as being significantly associated with neovascular
AMD risk. However, in both study designs (NEI and the
study presented here) these variants were only examined
for association with advanced stages of AMD, and it may
be that these variants are also associated with the early
forms of AMD as well. Further, we were able to demon-
strate the risk of AMD conferred by the joint effect of these
SNPs while controlling for smoking history, age and gen-
der. The most significant joint effect was between
rs10801575 (CFH) and rs2014307 (PLEKHA1/HTRA1) (P
< 10-11). After controlling for the effect of each SNP with
respect to the other, it was evident that this joint effect was
due to the significant assocation of SNP rs2014307 with
AMD risk, as the p value was greater for the PLEKHA1/
HTRA1  SNP (P  < 10-6) than it was for CFH  SNP
rs10801575, (P < 10-4). While these findings support the
contribution of chromosome 1q22-q32, they also dem-
onstrate that the 10q26 region is likely more stongly asso-
ciated with neovascular AMD risk [13,16-18]. It may be
that the dbGAP variants we analyzed on chromosomes
3p, 4q, 11q and 12q predispose an individual to the geo-
graphic atrophic subytpe. Whether or not these variants
represent true disease causing variants or are in high LD
with the susceptibilily allele remains to be determined.
We demonstrated that variants in the complement path-
way genes CFH, CFHR2, CFHR4 and CFHR5 are signifi-
cantly associated with AMD risk, however variants in
these genes may not be independent factors in the patho-
physiology of AMD due to the high LD throughout the
1q25-1q32 region [19-25].
We also demonstrated that significantly associated vari-
ants in F13B, ASPM, MAP2 and ZBTB41 point to other
pathways yet to be studied in AMD etiology. F13B is the
noncatalytic subunit of coagulation factor 13, which upon
activation by thrombin, functions to covalently cross-link
fibrin, making a clot mechanically stronger and more
resistant to fibrinolysis [26]. F13B is composed of 641
amino acids, divided into 10 tandem repeats, which is
characteristic of the complement activation system regula-
tory proteins [27] There is also a structural similarity
between F13B and CFH [28,29]. Both ASPM and MAP2
play a critical role during neurogenesis. ASPM regulates
brain growth and mutations in this gene were shown to be
associated with microcephaly [30-32]. Further ASPM has
been implicated in tumor cell proliferation and growth
[33] MAP2 stabilizes and interacts with microtubules dur-
ing the growth, differentiation, and development of neu-BMC Medical Genetics 2008, 9:51 http://www.biomedcentral.com/1471-2350/9/51
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rons [34,35]. Further, ZBTB41 proteins are transcription
regulators, functioning in a wide range of processes,
including development, differentiation, and oncogenesis
[36,37]. ZBTB41 proteins also play an important role in
the hematopoietic system, particularly in T cell develop-
ment and function [38].
Conclusion
In summary, this is the first report to confirm association
of neovascular AMD risk variants obtained from the NEI/
NCBI dbGAP database. Moreover, we show that specific
variants may predispose to only the neovascular form of
AMD, and in agreement with others, show that the 10q26
1a. Linkage disequilibrium (D') between the genotyped SNPs as shown in a heat map Figure 1
1a. Linkage disequilibrium (D') between the genotyped SNPs as shown in a heat map. SNPs encompassing 
the1q22-q32 region are represented by 3 distinct haplotype blocks. The more red the color, the higher the LD which is indi-
cated by the gradient bar to the right of the LD plot. 1b. Linkage disequilibrium (D') between the genotyped SNPs as shown in 
an LD plot. 1c. Haplotypes Haplotypes of SNPs together with estimated frequencies are shown. The values of multi-allelic D' 
(.79, .76, and .14) reflect the level of recombination between adjacent blocks. Abbreviations: bp, base pairs; SNP, Single 
Nucleotide Polymorphism; Linkage disequilibrium (D').BMC Medical Genetics 2008, 9:51 http://www.biomedcentral.com/1471-2350/9/51
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region is more strongly associated with neovascular AMD
risk than 1q.
Methods
Patient population
The protocol was reviewed and approved by the Institu-
tional Review Boards at the Massachusetts Eye & Ear Infir-
mary (MEEI), Boston, Massachusetts and the William
Beaumont Hospital, Royal Oak, Michigan and conforms
to the tenets of the Declaration of Helsinki. Eligible
patients were enrolled in this study after they gave
informed consent either in person, over the phone, or
through the mail, before answering questions to a stand-
ardized questionnaire and donating 10 to 50 ml of venous
blood.
Details of the recruitment of patients and their siblings are
described elsewhere [14,39]. In brief, all index patients
were aged 50 years or older and had the neovascular form
of AMD in at least one eye, defined by subretinal hemor-
rhage, fibrosis, or fluorescein angiographic presence of
neovascularization documented at the time of, or prior to,
enrollment in the study. Patients whose only exudative
finding was a retinal pigment epithelium detachment
were excluded because this finding may not represent def-
inite neovascular AMD and, therefore, the severe pheno-
type we sought. Patients with signs of pathologic myopia,
presumed ocular histoplasmosis syndrome, angioid
streaks, choroidal rupture, any hereditary retinal diseases
other than AMD, and previous laser treatment due to ret-
inal conditions other than AMD were also excluded.
The unaffected siblings had normal maculae at an age
older than that at which the index patient was first diag-
nosed with neovascular AMD. Normal maculae (defined
as the zone centered at the foveola and extending 2 disc
diameters, or 3000 microns, in radius) fulfilled the fol-
lowing criteria: 0–5 small drusen (all less than 63 microns
in diameter), no pigment abnormalities, no geographic
atrophy, and no neovascularization (as defined previ-
Table 1: Single SNP Analysis
SNP Gene* Location* 2 × 2 McNemar's 
test p-value
3 × 3 McNemar's 
test p-value
Likelihood Ratio 
Test p-value
Odds Ratio (95% 
C.I.) of most likely 
mode of inheritance
Likelihood Ratio 
Test Model
rs800292 CFH 1q32 0.0005 1.6766E-05 0.0020 0.295(0.126–0.693) Additive
rs572515 CFH 1q32 1.1422E-06 2.1771E-09 7.0012E-07 4.619(2.288–9.326) Additive
rs7529589 CFH 1q32 0.0003 1.6852E-05 1.2034E-05 8.403(2.670–26.442) Recessive
rs1061170 CFH 1q32 0.0002 3.9821E-05 1.9045E-05 7.382(2.495–21.838) Recessive
rs12038333 CFH 1q32 0.0001 1.7989E-06 8.3182E-06 3.151(1.707–5.819) Recessive
rs203674 CFH 1q32 5.7447E-06 5.0608E-08 4.3995E-06 3.914(2.020–7.585) Additive
rs10801575 ~CFH ~1q32 0.0304 0.0315 0.0108 0.370(0.174–0.785) Dominant
rs1853883 CFHR4 1q32 0.0001 6.9750E-06 0.0003 2.687(1.519–4.751) Additive
rs3790414 CFHR2 1q31-q32.1 0.0018 0.0002 0.0137 0.424(0.206–0.876) Additive
rs1759016 CFHR5 1q22-q23 0.0092 0.0037 0.0092 0.465(0.262–0.827) Additive
rs10922152 CFHR5 1q22-q23 0.0007 0.0001 0.0014 0.434(0.258–0.730) Additive
rs10922153 CFHR5 1q22-q23 0.0002 1.0290E-05 0.0004 0.389(0.224–0.677) Additive
rs6663083 ? 1q31-1q32 0.0003 1.6704E-05 0.0008 0.419(0.248–0.707) Additive
rs2990510 F13B 1q31-q32.1 0.0438 0.0395 0.1003 2.462(0.801–7.571) Recessive
rs6003 F13B 1q31-q32.1 0.0153 0.0022 0.0025 0.162(0.041–0.631) Additive
rs1412632 ? 1q31-1q32 0.0153 0.0022 0.0030 0.165(0.042–0.645) Additive
rs1412631 ? 1q31-1q32 0.0098 0.0005 0.0013 0.110(0.022–0.557) Additive
rs12677 ASPM 1q31 0.0098 0.0005 0.0019 0.127(0.026–0.609) Additive
rs4915337 ASPM 1q31 0.0614 0.0233 0.0067 0.182(0.045–0.740) Additive
rs1888991 ASPM 1q31 0.0244 0.0051 0.0044 0.175(0.044–0.696) Additive
rs6677082 ASPM 1q31 0.0244 0.0051 0.0048 0.175(0.044–0.695) Additive
rs6656448 ZBTB41 1q31.3 0.0218 0.0054 0.0042 0.209(0.063–0.694) Additive
rs9288410 MAP2 2q34-q35 0.5563 0.3721 0.0294 1.923(0.885–4.179) Recessive
rs304039 ITPR1 3p26-p25 0.6774 0.7070 0.1035 1.943(0.858–4.396) Recessive
rs304041 ITPR1 3p26-p25 0.5896 0.4206 0.1035 1.943(0.858–4.396) Recessive
rs1038639 ITPR1 3p26-p25 1.0000 0.9062 0.4345 0.731(0.332–1.610) Dominant
rs1447338 ? 4q34-4q35 0.5419 0.4856 0.2949 1.350(0.730–2.497) Additive
rs7090030 ADD3 10q24.2-q24.3 1.0000 1.0000 0.5834 0.485(0.035–6.710) Additive
rs11194995 ADD3 10q24.2-q24.3 1.0000 1.0000 0.5834 0.485(0.035–6.710) Additive
rs11194996 ADD3 10q24.2-q24.3 1.0000 1.0000 0.9217 0.881(0.071–10.862) Additive
rs11195001 ADD3 10q24.2-q24.3 1.0000 1.0000 1.0000 0.485(0.035–6.715) Additive
rs2014307 PLEKHA1/HTRA1 10q26 6.6872E-06 8.1056E-07 3.7092E-05 0.240(0.111–0.520) Additive
rs949252 GPR152 11q13.1 0.4795 0.4795 0.1979 2.006(0.115–35.135) Dominant
rs7124630 TMEM134 11q13.1 0.4795 0.0000 0.3864 1.004E-07(0.000-Inf) Additive
rs11575221 STAT2 12q13-12q14 1.0000 1.0000 0.4358 2.740(0.204–36.835) Additive
Abbreviations: SNP, single nucleotide polymorphism; C.I., confidence interval.
* Gene and location of each SNP determined using ENSEMBL [15].BMC Medical Genetics 2008, 9:51 http://www.biomedcentral.com/1471-2350/9/51
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ously [14,39]; AMD "category 1" or less on the AREDS
scale). Disease status of every participant was confirmed
by at least two of the investigators by evaluation of fundus
photographs or fluorescein angiograms except when one
of the investigators directly examined an unaffected sib-
ling during a home visit (n = 4 cases). Subject characteris-
tics of our extremely discordant sibpair population are
presented in Table 4.
Additionally, we administered a standardized question-
naire to all eligible participants in person or over the
phone to ascertain smoking exposure, with the age of the
index patient at the time of the fundus photographs as our
cutoff reference age for smoking exposure for both mem-
bers in a sibship. In most cases, the diagnosis of AMD was
made simultaneously with the diagnosis of neovascular
AMD. If a participant ever smoked, we recorded the age
when they started smoking, the age when they quit smok-
ing (if they did quit), and the number of packs of ciga-
rettes smoked per day, on average. Based on the responses,
the number of pack-years of cigarettes smoked was calcu-
lated for each smoker. Participants who smoked less than
100 cigarettes during their lifetime (i.e., less than 1/73 of
a pack-year) were categorized as having never smoked. A
pack-year was defined as one pack of cigarettes per day for
one year, with one pack defined as twenty cigarettes.
Genotyping Analysis
For both the Sequenom iPLEX system technology and
direct sequencing protocols, leukocyte DNA was either
purified by using standard phenol-chloroform or DNAzol
(Invitrogen Corporation, Carlsbad, California) extraction
protocols.
Multiplex PCR assays were designed using Sequenom
SpectroDESIGNER software (version 3.0.0.3) by inputting
sequence containing the SNP site and 100 bp of flanking
sequence on either side of the SNP. Briefly, 10 ng genomic
DNA was amplified in a 5 ul reaction containing 1 × Hot-
Star Taq PCR buffer (Qiagen), 1.625 mM MgCl2, 500 uM
each dNTP, 100 nM each PCR primer, 0.5 U HotStar Taq
(Qiagen). The reaction was incubated at 94°C for 15 min-
utes followed by 45 cycles of 94°C for 20 seconds, 56°C
for 30 seconds, 72°C for 1 minute, followed by 3 minutes
at 72°C. Excess dNTPs were then removed from the reac-
tion by incubation with 0.3 U shrimp alkaline phos-
phatase (USB) at 37°C for 40 minutes followed by 5
minutes at 85°C to deactivate the enzyme. Single primer
extension over the SNP was carried out in a final concen-
tration of between 0.625 uM and 1.5 uM for each exten-
sion primer (depending on the mass of the probe), iPLEX
termination mix (Sequenom) and 1.35 U iPLEX enzyme
(Sequenom) and cycled using a two-step 200 short cycles
program; 94°C for 30 seconds followed by 40 cycles of
94°C for 5 seconds, 5 cycles of 52°C for 5 seconds, and
80°C for 5 seconds, then 72°C for 3 minutes. The reaction
was then desalted by addition of 6 mg cation exchange
resin followed by mixing and centrifugation to settle the
contents of the tube. The extension product was then spot-
ted onto a 384 well spectroCHIP before being flown in the
MALDI-TOF mass spectrometer. Data was collected, real
time, using SpectroTYPER Analyzer 3.3.0.15, Spec-
traAQUIRE 3.3.1.1 and SpectroCALLER 3.3.0.14 (Seque-
nom). Additionally, to ensure data quality, genotypes for
each subject were also checked manually.
Six of the dbGAP SNPs (rs11575221, rs949252,
rs11194995, rs6656448, rs12677, rs6003) were not ame-
nable to genotyping by the Sequenom iPLEX system tech-
nology and thus were directly sequenced. Oligonucleotide
primers were selected using the Primer3 program [40] to
encompass the entire coding region and flanking intronic
sequences except in the case of an intronic SNP
Table 2: Legend of Figure 1.
ID rs number Chromosome Position (bp)
1 rs800292 1 169751219
2 rs572515 1 169755247
3 rs7529589 1 169767262
4 rs1061170 1 169768220
5 rs12038333 1 169781422
6 rs203674 1 169793601
7 rs10801575 1 169966624
8 rs1853883 1 169995661
9 rs3790414 1 170045770
10 rs1759016 1 170077967
11 rs10922152 1 170088475
12 rs10922153 1 170104084
13 rs6663083 1 170106129
14 rs2990510 1 170146127
15 rs6003 1 170156490
16 rs1412632 1 170162337
17 rs1412631 1 170162706
18 rs12677 1 170178842
19 rs4915337 1 170217004
20 rs1888991 1 170236289
21 rs6677082 1 170238000
22 rs6656448 1 170268765
23 rs9288410 2 204266059
24 rs304039 3 4490512
25 rs304041 3 4491054
26 rs1038639 3 4500754
27 rs1447338 4 178374405
28 rs7090030 10 105592344
29 rs11194995 10 105619802
30 rs11194996 10 105621397
31 rs11195001 10 105626325
32 rs2014307 10 117949887
33 rs949252 11 66975485
34 rs7124630 11 66997187
35 rs11575221 12 56407497BMC Medical Genetics 2008, 9:51 http://www.biomedcentral.com/1471-2350/9/51
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(rs6656448) where at least 100 base pairs on either side of
the variant was sequenced and analyzed (Table 5).
For all amplicons, the polymerase chain reaction (PCR)
was used to amplify genomic DNA fragments from 20 ng
of leukocyte DNA in a solution of 10× PCR buffer contain-
ing 25 mM of MgCl2, 0.2 mM each of dATP, dTTP, dGTP,
and dCTP, and 0.5 units of Taq DNA polymerase (USB
Corporation, Cleveland, OH). 5 M Betaine was added to
each PCR (Sigma-Aldrich, St. Louis, MO), except for the
reactions containing primers used to analyze rs12677 and
rs6003. The temperatures used during the polymerase
chain reaction were as follows: 95°C for 5 minutes fol-
lowed by 35 cycles of 58°C for 30 seconds, 72°C for 30
seconds and 95°C for 30 seconds, with a final annealing
at 58°C for 1.5 minutes and extension of 72°C for 5 min-
utes. For sequencing reactions, PCR products were
digested according to manufacturer's protocol with
ExoSAP-IT (USB Corporation, Cleveland, OH) then were
subjected to a cycle sequencing reaction using the Big Dye
Terminator v3.1 Cycle Sequencing kit (Applied Biosys-
tems, Foster City, CA) according to manufacturer's proto-
col. Products were purified with Performa DTR Ultra 96-
well plates (Edge Biosystems, Gaithersburg, MD) in order
to remove excess dye terminators. Samples were
sequenced on an ABI Prism 3100 DNA sequencer
(Applied Biosystems, Foster City, CA). Electropherograms
generated from the ABI Prism 3100 were analyzed using
the Lasergene DNA and protein analysis software (DNAS-
TAR, Inc., Madison, WI). Electropherograms were read by
two independent evaluators without knowledge of the
subject's disease status. All patients were sequenced in the
forward direction (5' to 3'), unless variants or polymor-
phisms were identified, in which case confirmation was
obtained in some cases by sequencing in the reverse direc-
tion.
Statistical Analyses
Statistical analysis was performed using the R and STATA
(v8) packages. The McNemar's test was used to evaluate
the effect of each SNP individually on risk of AMD. First
the standard 2 × 2 table was constructed, and then a mod-
ification of the McNemar's test using a 3 × 3 table,
 was also employed to compare the effect
of the three genotypes for each variant simultaneously. A
Bonferroni correction was applied to all resulting P values
T
bc
bc 1
1 2
=
−+
+
(| | )
Table 3: Pairwise SNP Analysis
SNP Interaction Joint effect of SNP and 
rs2014307
Effect of SNP, 
controlling for 
rs2014307
Odds Ratio (95% 
C.I.)
Effect of rs2014307, 
controlling for SNP
Odds Ratio (95% 
C.I.)
rs800292 0.034082688 1.51E-06 0.0005 0.369(0.151–0.899) 0.0193 0.271(0.122–0.603)
rs572515 0.560883637 2.03E-10 0.0003 4.817(2.236–10.379) 3.7602E-06 0.233(0.096–0.562)
rs7529589 0.454600765 7.27E-09 0.0007 7.861(2.283–27.066) 0.0001 0.260(0.112–0.605)
rs1061170 0.597380515 2.22E-08 0.0007 6.831(2.113–22.079) 0.0002 0.258(0.111–0.600)
rs12038333 0.393546389 4.22E-08 0.0006 2.884(1.512–5.503) 0.0004 0.272(0.121–0.609)
rs203674 0.463309999 2.68E-09 0.0007 3.721(1.847–7.496) 0.0001 0.256(0.109–0.603)
rs10801575 0.808299262 1.49E-11 4.0182E-05 0.309(0.135–0.710) 0.0078 0.194(0.079–0.475)
rs1853883 0.760773267 9.31E-08 0.0004 2.448(1.355–4.421) 0.0021 0.263(0.117–0.589)
rs3790414 0.088493626 2.96E-06 0.0001 0.463(0.213–1.004) 0.0411 0.252(0.115–0.554)
rs1759016 0.873846771 9.04E-07 0.0001 0.490(0.266–0.902) 0.0244 0.246(0.111–0.545)
rs10922152 0.876195836 1.15E-07 0.0002 0.484(0.282–0.831) 0.0056 0.245(0.107–0.558)
rs10922153 0.518399094 2.99E-09 0.0006 0.413(0.232–0.736) 0.0052 0.259(0.110–0.606)
rs6663083 0.989583181 6.89E-08 0.0001 0.443(0.258–0.761) 0.0015 0.223(0.095–0.523)
rs2990510 0.487660055 4.62E-06 3.9350E-05 2.894(0.874–9.585) 0.0684 0.222(0.099–0.499)
rs6003 0.454199074 4.15E-07 0.0001 0.151(0.035–0.649) 0.0048 0.222(0.098–0.501)
rs1412632 0.396769175 5.61E-07 0.0001 0.164(0.038–0.697) 0.0066 0.226(0.100–0.509)
rs1412631 0.64561949 2.26E-07 0.0001 0.113(0.021–0.592) 0.0025 0.234(0.104–0.527)
rs12677 0.500827762 5.73E-07 0.0002 0.132(0.025–0.707) 0.0068 0.239(0.108–0.528)
rs4915337 0.313727331 1.02E-06 0.0001 0.176(0.040–0.782) 0.0127 0.239(0.108–0.528)
rs1888991 0.454199074 4.15E-07 0.0001 0.151(0.035–0.649) 0.0048 0.222(0.098–0.501)
rs6677082 0.454199074 4.15E-07 4.8640E-05 0.151(0.035–0.649) 0.0048 0.222(0.098–0.501)
rs6656448 0.707806912 1.10E-06 0.0001 0.224(0.062–0.809) 0.0136 0.236(0.106–0.525)
Abbreviations: SNP, Single Nucleotide Polymorphism; C.I., Confidence Interval.
Table 4: Subject Characteristics
Population Mean Age (years) Range Standard Deviation % Male (n/134)
Affected Siblings 71.28 48.97–86.38 8.26 45.5% (61/134)
Unaffected Siblings 72.77 41.32–90.86 8.97 39.6% (53/134)BMC Medical Genetics 2008, 9:51 http://www.biomedcentral.com/1471-2350/9/51
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that were calculated for each allele of the 35 SNPs that met
these criteria. Linkage disequilibrium (r2) between adja-
cent SNPs on the same chromosome was evaluated. Both
SNPHAP and Phase were used separately in cases and con-
trols to reconstruct the diplotype (haplotype pair) for each
sample in each SNP group. The posterior probability for
any of the resulting diplotypes was calculated. The diplo-
type with the largest probability (> 0.80 for all of the sam-
ples) was picked up as the designated diplotype. For
haplotype analysis, SNPs that fit the following criteria
were analyzed: selected SNPs on the same chromosome,
adjacent SNPs in statistically significant LD, and minor
allele frequencies were similar. Both types of McNemar's
tests were then used to determine significant haplotypes.
Conditional logistic regression (CLR) was performed to
identify factors associated with neovascular AMD. Poten-
tial risk factors, SNPs, were evaluated initially one at a
time. Any significant allelic factors were then tested for
significance while controlling for age, gender and smok-
ing history. For each significant SNP, the minor allele (in
unaffected siblings) in both the homozygous and hetero-
zygous states versus the common allele in the
homozygous state was examined in the model. Gene-gene
interaction was tested first by assuming each locus had
two alleles, with three possible genotypes and 9 possible
two-locus genotypes. The likelihood ratio test (LRT) was
used to test the null hypothesis of no gene-gene interac-
tion (logarithm of odds ratio = 0). Three genotypic mod-
els were examined (Additive, Dominant, and Recessive)
using the likelihood ratio test.
Genotype and allele frequencies for all SNPs identified as
significant were calculated in the affected and separately
in unaffected siblings [see Additional File 1]. Deviation
from Hardy-Weinberg Equilibrium (HWE) was tested on
each SNP in unaffected (control) individuals using the chi
square test.
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